nefazodone (BioDeep_00000405955)

Main id: BioDeep_00000002094

 


代谢物信息卡片


nefazodone

化学式: C25H32ClN5O2 (469.2244)
中文名称: 奈法唑酮
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
InChI: InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3

描述信息

D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants
D049990 - Membrane Transport Modulators
Nefazodone is an orally active phenylpiperazine antidepressant. Nefazodone can potently and selectively block postsynaptic 5-HT2A receptors, and moderately inhibit 5-HT and noradrenaline reuptake. Nefazodone can also relieve the adverse effects of stress on the the immune system of mice. Nefazodone has a high affinity for CYP3A4 isoenzyme, which indicates that it has certain risk of agent-agent interaction[1][2][3].

同义名列表

2 个代谢物同义名

nefazodone; Nefazodone



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 6 ABCB1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4
Peripheral membrane protein 1 CYP2B6
Endosome membrane 1 SLC6A4
Endoplasmic reticulum membrane 6 CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4
cytosol 1 SCLY
dendrite 3 DRD2, HTR2A, HTR2C
Cell membrane 9 ABCB1, ABCB11, DRD2, HTR2A, HTR2C, KCNH2, SLC6A2, SLC6A4, TNF
Cell projection, axon 1 HTR2A
Multi-pass membrane protein 9 ABCB1, ABCB11, CACNA1I, DRD2, HTR2A, HTR2C, KCNH2, SLC6A2, SLC6A4
Golgi apparatus membrane 1 DRD2
Synapse 3 DRD2, HTR2C, SLC6A4
cell surface 5 ABCB1, ABCB11, KCNH2, SLC6A2, TNF
dendritic shaft 1 HTR2A
glutamatergic synapse 2 DRD2, HTR2A
Golgi apparatus 2 NPY, SCLY
Golgi membrane 2 ABCB11, DRD2
neuronal cell body 2 HTR2A, TNF
presynaptic membrane 4 DRD2, HTR2A, SLC6A2, SLC6A4
Cytoplasm, cytosol 1 SCLY
Presynapse 2 HTR2A, SLC6A4
acrosomal vesicle 1 DRD2
endosome 1 ABCB11
plasma membrane 12 ABCB1, ABCB11, CACNA1I, CYP2C19, CYP2C9, DRD2, HTR2A, HTR2C, KCNH2, SLC6A2, SLC6A4, TNF
synaptic vesicle membrane 2 DRD2, SLC6A2
Membrane 8 ABCB1, ABCB11, CACNA1I, CYP2D6, CYP3A4, KCNH2, SLC6A2, SLC6A4
apical plasma membrane 2 ABCB1, ABCB11
axon 3 DRD2, HTR2A, SLC6A2
caveola 1 HTR2A
extracellular exosome 2 ABCB1, ABCB11
endoplasmic reticulum 1 CYP2D6
extracellular space 2 NPY, TNF
perinuclear region of cytoplasm 1 KCNH2
intercellular canaliculus 1 ABCB11
mitochondrion 1 CYP2D6
intracellular membrane-bounded organelle 6 CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4
Microsome membrane 5 CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP3A4
Secreted 1 NPY
extracellular region 2 NPY, TNF
Single-pass membrane protein 1 CYP2D6
neuronal cell body membrane 1 SLC6A2
ciliary membrane 1 DRD2
external side of plasma membrane 1 TNF
dendritic spine 1 DRD2
perikaryon 1 DRD2
cytoplasmic vesicle 1 HTR2A
recycling endosome 2 ABCB11, TNF
Single-pass type II membrane protein 1 TNF
postsynaptic membrane 3 DRD2, HTR2A, SLC6A4
Apical cell membrane 2 ABCB1, ABCB11
Membrane raft 2 SLC6A4, TNF
Cell junction, focal adhesion 1 SLC6A4
focal adhesion 1 SLC6A4
GABA-ergic synapse 2 DRD2, NPY
lateral plasma membrane 1 DRD2
Cell projection, neuron projection 1 SLC6A4
neuron projection 1 SLC6A4
cilium 1 DRD2
phagocytic cup 1 TNF
non-motile cilium 1 DRD2
sperm flagellum 1 DRD2
Recycling endosome membrane 1 ABCB11
Endomembrane system 1 SLC6A4
Membrane, caveola 1 HTR2A
monoatomic ion channel complex 1 KCNH2
cell body fiber 1 HTR2A
Cell projection, dendrite 1 HTR2A
inward rectifier potassium channel complex 1 KCNH2
voltage-gated potassium channel complex 1 KCNH2
axon terminus 1 DRD2
voltage-gated calcium channel complex 1 CACNA1I
endocytic vesicle 1 DRD2
neuronal dense core vesicle 1 NPY
neurofilament 1 HTR2A
external side of apical plasma membrane 1 ABCB1
dopaminergic synapse 1 DRD2
intracellular canaliculus 1 ABCB11
Cytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle 1 NPY
[Tumor necrosis factor, soluble form]: Secreted 1 TNF
catalytic complex 1 SCLY
G protein-coupled receptor complex 1 DRD2
G protein-coupled serotonin receptor complex 2 HTR2A, HTR2C
serotonergic synapse 1 SLC6A4
[C-domain 2]: Secreted 1 TNF
[Tumor necrosis factor, membrane form]: Membrane 1 TNF
[C-domain 1]: Secreted 1 TNF


文献列表

  • Hong Wei, Albert P Li. Permeabilized Cryopreserved Human Hepatocytes as an Exogenous Metabolic System in a Novel Metabolism-Dependent Cytotoxicity Assay for the Evaluation of Metabolic Activation and Detoxification of Drugs Associated with Drug-Induced Liver Injuries: Results with Acetaminophen, Amiodarone, Cyclophosphamide, Ketoconazole, Nefazodone, and Troglitazone. Drug metabolism and disposition: the biological fate of chemicals. 2022 02; 50(2):140-149. doi: 10.1124/dmd.121.000645. [PMID: 34750194]
  • Rajkapoor Balasubramanian, Naina M P Maideen. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview. Current drug metabolism. 2021; 22(5):328-341. doi: 10.2174/1389200222666210114122729. [PMID: 33459228]
  • Dorota Żelaszczyk, Magdalena Jakubczyk, Karolina Pytka, Anna Rapacz, Maria Walczak, Paulina Janiszewska, Katarzyna Pańczyk, Paweł Żmudzki, Karolina Słoczyńska, Henryk Marona, Anna M Waszkielewicz. Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system. Bioorganic & medicinal chemistry letters. 2019 11; 29(21):126679. doi: 10.1016/j.bmcl.2019.126679. [PMID: 31537425]
  • Naoyuki Nakada, Akio Kawamura, Hidetaka Kamimura, Koya Sato, Yasuhiro Kazuki, Masakazu Kakuni, Masato Ohbuchi, Kota Kato, Chise Tateno, Mitsuo Oshimura, Takashi Usui. Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans. Biopharmaceutics & drug disposition. 2016 Jan; 37(1):3-14. doi: 10.1002/bdd.1990. [PMID: 26352195]
  • W Mattes, K Davis, E Fabian, J Greenhaw, M Herold, R Looser, W Mellert, S Groeters, H Marxfeld, N Moeller, G Montoya-Parra, A Prokoudine, B van Ravenzwaay, V Strauss, T Walk, H Kamp. Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma. Toxicology letters. 2014 Nov; 230(3):467-78. doi: 10.1016/j.toxlet.2014.07.021. [PMID: 25086301]
  • Cho-Ming Loi, Dennis A Smith, Deepak Dalvie. Which metabolites circulate?. Drug metabolism and disposition: the biological fate of chemicals. 2013 May; 41(5):933-51. doi: 10.1124/dmd.112.050278. [PMID: 23454828]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Britta Haenisch, Eva Drescher, Lidia Thiemer, Hu Xin, Bruno Giros, Sophie Gautron, Heinz Bönisch. Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3. Naunyn-Schmiedeberg's archives of pharmacology. 2012 Oct; 385(10):1017-23. doi: 10.1007/s00210-012-0781-8. [PMID: 22806583]
  • Sarah Dawson, Simone Stahl, Nikki Paul, Jane Barber, J Gerald Kenna. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug metabolism and disposition: the biological fate of chemicals. 2012 Jan; 40(1):130-8. doi: 10.1124/dmd.111.040758. [PMID: 21965623]
  • Guilherme A Behr, José C F Moreira, Benicio N Frey. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxidative medicine and cellular longevity. 2012; 2012(?):609421. doi: 10.1155/2012/609421. [PMID: 22693652]
  • Hee Jeong Seo, Eun-Jung Park, Min Ju Kim, Suk Youn Kang, Suk Ho Lee, Hyun Jung Kim, Ki Nam Lee, Myung Eun Jung, Minwoo Lee, Mi-Soon Kim, Eun-Jung Son, Woo-Kyu Park, Jeongmin Kim, Jinhwa Lee. Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter. Journal of medicinal chemistry. 2011 Sep; 54(18):6305-18. doi: 10.1021/jm200682b. [PMID: 21823597]
  • Riccardo Davanzo, Marco Copertino, Angela De Cunto, Federico Minen, Alessandro Amaddeo. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine. 2011 Apr; 6(2):89-98. doi: 10.1089/bfm.2010.0019. [PMID: 20958101]
  • Antonio R Chacra. Saxagliptin for type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy. 2010 Sep; 3(?):325-35. doi: 10.2147/dmsott.s12241. [PMID: 21437102]
  • O Me Abdel Salam, A A Sleem, N Shafee. Effect of trazodone and nefazodone on hepatic injury induced by carbon tetrachloride. Drug discoveries & therapeutics. 2010 Aug; 4(4):285-97. doi: . [PMID: 22491211]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Angelo A Izzo, Edzard Ernst. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009; 69(13):1777-98. doi: 10.2165/11317010-000000000-00000. [PMID: 19719333]
  • Peter H Silverstone, Robert Williams, Louis McMahon, Rosanna Fleming, Siobhan Fogarty. Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice. Annals of general psychiatry. 2008 Oct; 7(?):19. doi: 10.1186/1744-859x-7-19. [PMID: 18922171]
  • S C Collins, A Salehi, L Eliasson, C S Olofsson, P Rorsman. Long-term exposure of mouse pancreatic islets to oleate or palmitate results in reduced glucose-induced somatostatin and oversecretion of glucagon. Diabetologia. 2008 Sep; 51(9):1689-93. doi: 10.1007/s00125-008-1082-0. [PMID: 18622593]
  • Edoardo Spina, Vincenza Santoro, Concetta D'Arrigo. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clinical therapeutics. 2008 Jul; 30(7):1206-27. doi: 10.1016/s0149-2918(08)80047-1. [PMID: 18691982]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Benjamin Chanrion, Clotilde Mannoury la Cour, Sophie Gavarini, Mathieu Seimandi, Laurent Vincent, Jean-François Pujol, Joël Bockaert, Philippe Marin, Mark J Millan. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Molecular pharmacology. 2008 Mar; 73(3):748-57. doi: 10.1124/mol.107.041574. [PMID: 18083778]
  • Mark Waterlow, Paul Chrisp. Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome. Core evidence. 2008 Feb; 2(3):173-87. doi: ". [PMID: 21221184]
  • Roland F Staack, Liane D Paul, Dagmar Schmid, Gabriele Roider, Burkhard Rolf. Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions?. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Aug; 855(2):127-33. doi: 10.1016/j.jchromb.2007.05.017. [PMID: 17574934]
  • Ahsan Y Khan, Sheldon H Preskorn, W Dale Horst. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study. JPMA. The Journal of the Pakistan Medical Association. 2007 May; 57(5):230-5. doi: . [PMID: 17571477]
  • Yan Mao, Mike-Qingtao Huang, Yuan-Qing Xia, Mohammed Jemal. High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2007 Apr; 43(5):1808-19. doi: 10.1016/j.jpba.2006.11.041. [PMID: 17236738]
  • Pierre Blier, Elise Saint-André, Chantal Hébert, Claude de Montigny, Normand Lavoie, Guy Debonnel. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. The international journal of neuropsychopharmacology. 2007 Feb; 10(1):41-50. doi: 10.1017/s1461145705006395. [PMID: 16690005]
  • Austin C Li, Mark A Gohdes, Wilson Z Shou. 'N-in-one' strategy for metabolite identification using a liquid chromatography/hybrid triple quadrupole linear ion trap instrument using multiple dependent product ion scans triggered with full mass scan. Rapid communications in mass spectrometry : RCM. 2007; 21(8):1421-30. doi: 10.1002/rcm.2976. [PMID: 17377936]
  • Mingshe Zhu, Li Ma, Donglu Zhang, Kenneth Ray, Weiping Zhao, W Griffith Humphreys, Gary Skiles, Mark Sanders, Haiying Zhang. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug metabolism and disposition: the biological fate of chemicals. 2006 Oct; 34(10):1722-33. doi: 10.1124/dmd.106.009241. [PMID: 16815965]
  • Seva E Kostrubsky, Stephen C Strom, Amit S Kalgutkar, Shaila Kulkarni, James Atherton, Rouchelle Mireles, Bo Feng, Raylene Kubik, Janean Hanson, Ellen Urda, Abdul E Mutlib. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicological sciences : an official journal of the Society of Toxicology. 2006 Apr; 90(2):451-9. doi: 10.1093/toxsci/kfj095. [PMID: 16410371]
  • Domenic A Ciraulo, Clifford Knapp, John Rotrosen, Ofra Sarid-Segal, Ann Marie Ciraulo, Joseph LoCastro, David J Greenblatt, Deborah Leiderman. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction (Abingdon, England). 2005 Mar; 100 Suppl 1(?):23-31. doi: 10.1111/j.1360-0443.2005.00984.x. [PMID: 15730347]
  • Holger Jahn, Mildred Schick, Falk Kiefer, Michael Kellner, Alexander Yassouridis, Klaus Wiedemann. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Archives of general psychiatry. 2004 Dec; 61(12):1235-44. doi: 10.1001/archpsyc.61.12.1235. [PMID: 15583115]
  • Monika Szewczuk-Bogusławska, Magdalena Grzesiak, Jan Aleksander Beszłej, Andrzej Kiejna. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy]. Psychiatria polska. 2004 Nov; 38(6):1093-104. doi: . [PMID: 15779673]
  • Oliver Köhnlein, Rita Lutz, Max Schmauss, Thomas Messer. [Determining serum concentrations of the modern antipsychotic quetiapin: clinical relevance in therapeutic drug monitoring]. Psychiatrische Praxis. 2004 Nov; 31 Suppl 1(?):S175-7. doi: 10.1055/s-2004-828464. [PMID: 15570545]
  • A A Izzo. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. International journal of clinical pharmacology and therapeutics. 2004 Mar; 42(3):139-48. doi: 10.5414/cpp42139. [PMID: 15049433]
  • Franco Lombardo, R Scott Obach, Marina Y Shalaeva, Feng Gao. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry. 2004 Feb; 47(5):1242-50. doi: 10.1021/jm030408h. [PMID: 14971904]
  • S G O'Brien, P Meinhardt, E Bond, J Beck, B Peng, C Dutreix, G Mehring, S Milosavljev, C Huber, R Capdeville, T Fischer. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British journal of cancer. 2003 Nov; 89(10):1855-9. doi: 10.1038/sj.bjc.6601152. [PMID: 14612892]
  • François Lespérance, Nancy Frasure-Smith, Marc-André Laliberté, Michel White, Sylvain Lafontaine, Angelino Calderone, Mario Talajic, Jean-L Rouleau. An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2003 Nov; 48(10):695-701. doi: 10.1177/070674370304801009. [PMID: 14674053]
  • Roland F Staack, Hans H Maurer. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. Journal of analytical toxicology. 2003 Nov; 27(8):560-8. doi: 10.1093/jat/27.8.560. [PMID: 14670134]
  • Edoardo Spina, Maria Gabriella Scordo, Concetta D'Arrigo. Metabolic drug interactions with new psychotropic agents. Fundamental & clinical pharmacology. 2003 Oct; 17(5):517-38. doi: 10.1046/j.1472-8206.2003.00193.x. [PMID: 14703714]
  • Bengi Uslu, Sibel A Ozkan. Electroanalytical characteristics of piribedil and its differential pulse and square wave voltammetric determination in pharmaceuticals and human serum. Journal of pharmaceutical and biomedical analysis. 2003 Mar; 31(3):481-9. doi: 10.1016/s0731-7085(02)00725-2. [PMID: 12615235]
  • Amit S Kalgutkar, Timothy J Taylor, Karthik Venkatakrishnan, Emre M Isin. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug metabolism and disposition: the biological fate of chemicals. 2003 Mar; 31(3):243-9. doi: 10.1124/dmd.31.3.243. [PMID: 12584149]
  • María J Núñez, Maravillas Rivas, Pilar Riveiro, Juan Suárez, José Balboa, Luis A Núñez, Manuel Rey-Méndez, Manuel Freire-Garabal. Effects of nefazodone on voluntary ethanol consumption induced by isolation stress in young and aged rats. Pharmacology, biochemistry, and behavior. 2002 Oct; 73(3):689-96. doi: 10.1016/s0091-3057(02)00875-4. [PMID: 12151045]
  • Franco Lombardo, R Scott Obach, Marina Y Shalaeva, Feng Gao. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. Journal of medicinal chemistry. 2002 Jun; 45(13):2867-76. doi: 10.1021/jm0200409. [PMID: 12061889]
  • Ulrich Klotz. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittel-Forschung. 2002; 52(3):155-61. doi: 10.1055/s-0031-1299873. [PMID: 11963641]
  • C P Alderman, M G Gebauer, A L Gilbert, J T Condon. Possible interaction of zopiclone and nefazodone. The Annals of pharmacotherapy. 2001 Nov; 35(11):1378-80. doi: 10.1345/aph.1a074. [PMID: 11724087]
  • T Wobrock, B Schwaab, M Böhm, H J Schäfers, K Wanke, T Supprian. [Pharmacotherapeutical approaches to insomnia patients with cardiac diseases and after heart transplantation]. Zeitschrift fur Kardiologie. 2001 Oct; 90(10):717-28. doi: 10.1007/s003920170091. [PMID: 11757467]
  • A Y Khan, S H Preskorn. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. The Journal of clinical psychiatry. 2001 May; 62(5):375-6. doi: 10.4088/jcp.v62n0512d. [PMID: 11411823]
  • D Wuerth, S H Finkelstein, J Ciarcia, R Peterson, A S Kliger, F O Finkelstein. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2001 May; 37(5):1011-7. doi: 10.1016/s0272-6386(05)80018-6. [PMID: 11325684]
  • M Yao, L Chen, N R Srinivas. Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. Journal of chromatography. B, Biomedical sciences and applications. 2001 Mar; 752(1):9-16. doi: 10.1016/s0378-4347(00)00505-3. [PMID: 11254202]
  • P J Goodnick. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2001 Mar; 13(1):31-41. doi: 10.1023/a:1009012815127. [PMID: 11465683]
  • D R Abernethy, J T Barbey, J Franc, K S Brown, I Feirrera, N Ford, D E Salazar. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. Clinical pharmacology and therapeutics. 2001 Mar; 69(3):96-103. doi: 10.1067/mcp.2001.114230. [PMID: 11240972]
  • J Bickeboeller-Friedrich, H H Maurer. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Therapeutic drug monitoring. 2001 Feb; 23(1):61-70. doi: 10.1097/00007691-200102000-00012. [PMID: 11206046]
  • C L DeVane, J S Markowitz, H L Liston, S C Risch. Charleston Antidepressant Drug Interactions Surveillance Program (CADISP). Psychopharmacology bulletin. 2001; 35(2):50-61. doi: NULL. [PMID: 12397886]
  • M Jemal, M Huang, Y Mao, D Whigan, M L Powell. Increased throughput in quantitative bioanalysis using parallel-column liquid chromatography with mass spectrometric detection. Rapid communications in mass spectrometry : RCM. 2001; 15(12):994-9. doi: 10.1002/rcm.330. [PMID: 11400209]
  • P T Ninan. Pharmacokinetically induced benzodiazepine withdrawal. Psychopharmacology bulletin. 2001; 35(4):94-100. doi: NULL. [PMID: 12397859]
  • J L Seabolt, O A De León. Response to nefazodone in a depressed patient with end-stage renal disease. General hospital psychiatry. 2001 Jan; 23(1):45-6. doi: 10.1016/s0163-8343(00)00120-1. [PMID: 11291641]
  • A A Izzo, E Ernst. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001; 61(15):2163-75. doi: 10.2165/00003495-200161150-00002. [PMID: 11772128]
  • P Yapp, K F Ilett, J H Kristensen, L P Hackett, M J Paech, J Rampono. Drowsiness and poor feeding in a breast-fed infant: association with nefazodone and its metabolites. The Annals of pharmacotherapy. 2000 Nov; 34(11):1269-72. doi: 10.1345/aph.10120. [PMID: 11098340]
  • I A Pullar, S L Carney, E M Colvin, V L Lucaites, D L Nelson, S Wedley. LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. European journal of pharmacology. 2000 Oct; 407(1-2):39-46. doi: 10.1016/s0014-2999(00)00728-7. [PMID: 11050288]
  • M Yao, N R Srinivas. Simultaneous quantitation of d7-nefazodone, nefazodone, d7-hydroxynefazodone, hydroxynefazodone, m-chlorophenylpiperazine and triazole-dione in human plasma by liquid chromatographic-mass spectrometry. Biomedical chromatography : BMC. 2000 Apr; 14(2):106-12. doi: 10.1002/(sici)1099-0801(200004)14:2<106::aid-bmc934>3.0.co;2-0. [PMID: 10694704]
  • C Laroudie, D E Salazar, J P Cosson, B Cheuvart, B Istin, J Girault, I Ingrand, J P Decourt. Carbamazepine-nefazodone interaction in healthy subjects. Journal of clinical psychopharmacology. 2000 Feb; 20(1):46-53. doi: 10.1097/00004714-200002000-00009. [PMID: 10653208]
  • S Dodd, A Buist, G D Burrows, K P Maguire, T R Norman. Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breast milk by high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications. 1999 Jul; 730(2):249-55. doi: 10.1016/s0378-4347(99)00225-x. [PMID: 10448960]
  • D Taylor, M Bodani, A Hubbeling, R Murray. The effect of nefazodone on clozapine plasma concentrations. International clinical psychopharmacology. 1999 May; 14(3):185-7. doi: NULL. [PMID: 10435773]
  • C Laroudie, D E Salazar, J P Cosson, B Cheuvart, B Istin, J Girault, I Ingrand, J P Decourt. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects. European journal of clinical pharmacology. 1999 Feb; 54(12):923-8. doi: 10.1007/s002280050576. [PMID: 10192752]
  • C L DeVane, B G Pollock. Pharmacokinetic considerations of antidepressant use in the elderly. The Journal of clinical psychiatry. 1999; 60 Suppl 20(?):38-44. doi: NULL. [PMID: 10513858]
  • A Nacca, G Guiso, C Fracasso, L Cervo, S Caccia. Brain-to-blood partition and in vivo inhibition of 5-hydroxytryptamine reuptake and quipazine-mediated behaviour of nefazodone and its main active metabolites in rodents. British journal of pharmacology. 1998 Dec; 125(7):1617-23. doi: 10.1038/sj.bjp.0702251. [PMID: 9884092]
  • A J Olyaei, A M deMattos, D J Norman, W M Bennett. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy. 1998 Nov; 18(6):1356-9. doi: . [PMID: 9855339]
  • J V Campo, C Smith, J M Perel. Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent. Archives of general psychiatry. 1998 Nov; 55(11):1050-2. doi: 10.1001/archpsyc.55.11.1050-a. [PMID: 9819077]
  • M Yao, V R Shah, W C Shyu, N R Srinivas. Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. Journal of chromatography. B, Biomedical sciences and applications. 1998 Oct; 718(1):77-85. doi: 10.1016/s0378-4347(98)00355-7. [PMID: 9832363]
  • K Rickels, E Schweizer, W G Case, N DeMartinis, D J Greenblatt, L A Mandos, F G Garcia España. Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. Journal of clinical psychopharmacology. 1998 Apr; 18(2):145-53. doi: 10.1097/00004714-199804000-00007. [PMID: 9580369]
  • M Jurima-Romet, M Wright, S Neigh. Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes. British journal of clinical pharmacology. 1998 Mar; 45(3):318-21. doi: 10.1046/j.1365-2125.1998.00681.x. [PMID: 10896409]
  • M Narayan, G Anderson, J Cellar, R T Mallison, L H Price, J C Nelson. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. Journal of clinical psychopharmacology. 1998 Feb; 18(1):67-71. doi: 10.1097/00004714-199802000-00011. [PMID: 9472845]
  • J P Vella, M H Sayegh. Interactions between cyclosporine and newer antidepressant medications. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1998 Feb; 31(2):320-3. doi: 10.1053/ajkd.1998.v31.pm9469504. [PMID: 9469504]
  • M J Owens, W N Morgan, S J Plott, C B Nemeroff. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. The Journal of pharmacology and experimental therapeutics. 1997 Dec; 283(3):1305-22. doi: NULL. [PMID: 9400006]
  • D S Greene, R H Barbhaiya. Clinical pharmacokinetics of nefazodone. Clinical pharmacokinetics. 1997 Oct; 33(4):260-75. doi: 10.2165/00003088-199733040-00002. [PMID: 9342502]
  • R J Goldberg. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Drugs & aging. 1997 Aug; 11(2):119-31. doi: 10.2165/00002512-199711020-00004. [PMID: 9259175]
  • M R Marino, K M Langenbacher, J L Hammett, P Nichola, H D Uderman. The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects. Journal of clinical psychopharmacology. 1997 Feb; 17(1):27-33. doi: 10.1097/00004714-199702000-00006. [PMID: 9004054]
  • R H Barbhaiya, A B Buch, D S Greene. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. British journal of clinical pharmacology. 1996 Nov; 42(5):573-81. doi: 10.1111/j.1365-2125.1996.tb00112.x. [PMID: 8951188]
  • K M Helms-Smith, S L Curtis, R C Hatton. Apparent interaction between nefazodone and cyclosporine. Annals of internal medicine. 1996 Sep; 125(5):424. doi: 10.7326/0003-4819-125-5-199609010-00026. [PMID: 8702104]
  • R H Barbhaiya, A B Buch, D S Greene. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. Journal of clinical psychopharmacology. 1996 Feb; 16(1):19-25. doi: 10.1097/00004714-199602000-00004. [PMID: 8834414]
  • R H Barbhaiya, U A Shukla, D S Greene, H P Breul, K K Midha. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. Journal of clinical psychopharmacology. 1996 Feb; 16(1):26-34. doi: 10.1097/00004714-199602000-00005. [PMID: 8834415]
  • R C Dockens, D S Greene, R H Barbhaiya. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. Journal of clinical pharmacology. 1996 Feb; 36(2):160-7. doi: 10.1002/j.1552-4604.1996.tb04181.x. [PMID: 8852392]
  • D S Robinson, D L Roberts, J M Smith, J C Stringfellow, S B Kaplita, J A Seminara, R N Marcus. The safety profile of nefazodone. The Journal of clinical psychiatry. 1996; 57 Suppl 2(?):31-8. doi: . [PMID: 8626361]
  • R H Barbhaiya, U A Shukla, P Chaikin, D S Greene, P H Marathe. Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation. European journal of clinical pharmacology. 1996; 50(1-2):101-7. doi: 10.1007/s002280050076. [PMID: 8739819]
  • P H Marathe, J S Lee, D S Greene, R H Barbhaiya. Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening. British journal of clinical pharmacology. 1996 Jan; 41(1):21-7. doi: 10.1111/j.1365-2125.1996.tb00154.x. [PMID: 8824689]
  • R H Barbhaiya, K A Dandekar, D S Greene. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. Drug metabolism and disposition: the biological fate of chemicals. 1996 Jan; 24(1):91-5. doi: NULL. [PMID: 8825195]
  • D S Greene, D E Salazar, R C Dockens, P Kroboth, R H Barbhaiya. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. Journal of clinical psychopharmacology. 1995 Dec; 15(6):399-408. doi: 10.1097/00004714-199512000-00003. [PMID: 8748428]
  • R C Dockens, D Rapoport, D Roberts, D S Greene, R H Barbhaiya. Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. British journal of clinical pharmacology. 1995 Dec; 40(6):598-601. doi: 10.1111/j.1365-2125.1995.tb05806.x. [PMID: 8703669]
  • D S Greene, D E Salazar, R C Dockens, P Kroboth, R H Barbhaiya. Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. Journal of clinical psychopharmacology. 1995 Dec; 15(6):409-16. doi: 10.1097/00004714-199512000-00004. [PMID: 8748429]
  • D E Salazar, P H Marathe, I E Fulmor, J S Lee, R H Raymond, H D Uderman. Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. Journal of clinical pharmacology. 1995 Nov; 35(11):1109-18. doi: 10.1002/j.1552-4604.1995.tb04035.x. [PMID: 8626885]
  • R H Barbhaiya, U A Shukla, C S Natarajan, D A Behr, D S Greene, S M Sainati. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clinical pharmacology and therapeutics. 1995 Oct; 58(4):390-8. doi: 10.1016/0009-9236(95)90051-9. [PMID: 7586930]
  • R H Barbhaiya, U A Shukla, P D Kroboth, D S Greene. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. Journal of clinical psychopharmacology. 1995 Oct; 15(5):320-6. doi: 10.1097/00004714-199510000-00003. [PMID: 8830062]
  • R H Barbhaiya, P H Marathe, D S Greene, R F Mayol, U A Shukla, R R Gammans, K A Pittman, D Robinson. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study. Journal of clinical pharmacology. 1995 Oct; 35(10):974-84. doi: 10.1002/j.1552-4604.1995.tb04013.x. [PMID: 8568015]
  • S Kaul, U A Shukla, R H Barbhaiya. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. Journal of clinical pharmacology. 1995 Aug; 35(8):830-9. doi: 10.1002/j.1552-4604.1995.tb04127.x. [PMID: 8522641]
  • R H Barbhaiya, U A Shukla, D S Greene. Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. British journal of clinical pharmacology. 1995 Aug; 40(2):161-5. doi: 10.1111/j.1365-2125.1995.tb05771.x. [PMID: 8562300]
  • D E Salazar, R C Dockens, R L Milbrath, R H Raymond, I E Fulmor, P C Chaikin, H D Uderman. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. Journal of clinical pharmacology. 1995 Jul; 35(7):730-8. doi: 10.1002/j.1552-4604.1995.tb04114.x. [PMID: 7560254]
  • M W van Laar, A P van Willigenburg, E R Volkerts. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. Journal of clinical psychopharmacology. 1995 Feb; 15(1):30-40. doi: 10.1097/00004714-199502000-00006. [PMID: 7714226]
  • M J Owens, J R Ieni, D L Knight, K Winders, C B Nemeroff. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life sciences. 1995; 57(24):PL373-80. doi: 10.1016/0024-3205(95)02222-5. [PMID: 7475971]
  • R H Barbhaiya, U A Shukla, D S Greene. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. European journal of clinical pharmacology. 1995; 49(3):221-8. doi: 10.1007/bf00192383. [PMID: 8665999]